We share your passion for science. Promega is committed to excellence in technologies to assess key processes in PROTAC-induced protein degradation: compound binding and permeability, ternary complex formation, ubiquitination, and trafficking to proteasome. Assay live cells in kinetic mode to determine target protein degradation rates, DC50 potency values, and recovery profiles. Let’s collaborate.
Delve deeper into examining key targets involved in drug discovery, oncology, gene therapy and neurodegenerative disorders. Identify the critical molecules that influence targeted-protein degradation pathways with characterization tools from NanoTemper Technologies. We’re committed to enabling researchers to easily, efficiently, and precisely characterize proteins. With systems, software and consumables for evaluating and screening binding affinities, protein stability and protein quality, scientists in academia, biotech and pharmaceuticals will experience improved workflows and quality results.
LifeSensors generates reagents and drug discovery platforms which enable researchers to accurately and effectively assay the Ubiquitin Proteasome System. In addition to off-the-shelf products and kits, LifeSensors also partners with companies and researchers around the world to develop novel drug discovery assays. LifeSensors’ powerful technologies in conjunction with our expertise in the UPS, have enabled researchers to target and assay the undruggable targets.
At MilliporeSigma, our purpose is to solve the toughest problems in life science. To accelerate discovery for Targeted Protein Degradation, our Sigma-Aldrich Chemical Biology portfolio simplifies synthesis and library generation of protein degraders with degrader building blocks and custom synthesis capabilities. In addition to new degrader probes and lead discovery tools, TPD research is supported through our extensive offerings in bioactive small molecules, antibodies, western blotting, and genome editing tools such as CRISPR.
Nanome is changing how we understand, design, and interact with science. Nanome’s immersive virtual workspaces allow users to visualize, modify, and simulate chemical compounds, proteins, and nucleic acids to help improve the Drug Discovery process. Our virtual reality platform facilitates effective communication of structural data in drug discovery which has proved beneficial to several pharmaceutical and biotech companies across the globe. This is especially helpful for organizations that are interested in improving their cross-site collaboration.
Refeyn pioneers mass photometry technology, producing a disruptive new generation of analytical instruments. The instruments quickly and simply measure the mass of individual molecules directly in solution without needing labels. Refeyn is transforming scientists’ abilities to characterise the function, structural composition and dynamics of biomolecules in near-native environments.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
Bio-Techne brings together some of the most referenced brands in life science to provide innovative tools for Targeted Protein Degradation. Boston Biochem are world leaders in ubiquitin-proteasome system-related products, Tocris Bioscience are market leaders for research tool Degraders and Degrader building blocks while ProteinSimple provide automated platforms for detecting and quantifying protein degradation via Western Blot. Together we are Bio-Techne. Find out how we can help you achieve your research goals.
Beacon Targeted Therapies
We are a competitive and research intelligence database solution designed in partnership with pharmaceutical professionals across the world working in targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Aragen Life Sciences Pvt Ltd (Aragen) is a global leader in providing discovery, development and manufacturing solutions for life sciences firms. With a team of over 3100 professionals, and through a network of sites around the world, we offer a seamless, integrated platform to advance customer programs from discovery through commercialization for both small molecules and biologics. Established in 2001, Aragen now serves over 450 customers worldwide across multiple modalities and therapeutic areas.
BioDuro-Sundia, an Advent International portfolio company, is a leading contract research, development and manufacturing organization (CRDMO) that provides biopharmaceutical partners with fully integrated services to support drug discovery, development and manufacturing for both drug substance and drug product. The company is the industry’s third largest, with operations in China and the US—featuring more than 2,000 employees and 10 global sites.
Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement for poorly soluble compounds. Partner with us to accelerate your discovery and de-risk development.
Target protein degraders push the boundaries of medicine. TPDs also push the boundaries of analytical chemistry. SCIEX has a long-standing record of working with you to enable innovative mass spectrometry and CE-based solutions. Whether you are in early discovery or further along the path to commercialization, SCIEX offers a comprehensive portfolio of hardware and software. Let’s talk about your analytical challenges.
Digital Science is a technology company working to make research more efficient. We invest in, nurture and support innovative businesses and technologies that make all parts of the research process more open and effective. We believe that together, we can help researchers make a difference.
Nurix is committed to bringing novel, first-in-class therapies to patients who do not have adequate treatment options. At Nurix, we have applied our deep E3 ligase expertise and internally developed DNA-encoded libraries (DEL) to develop the DELigase platform for Targeted Protein Modulation. DELigase can harness the activity of specific E3 ligases to destroy disease-causing proteins, an approach known as Targeted Protein Degradation, or inhibit specific E3 ligases to increase levels of beneficial proteins.
Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston’s “Best Places to Work.”
HitGen, Inc. is a biotech company focused on DNA Encoded Library development and applications. HitGen’s DELs currently contain more than 500 billion novel, diverse and drug-like small molecules, which are synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results on challenging targets such as PPI with high affinity. HitGen has also developed unique DELs and methods for identification of small molecules that can be used for targeted protein degradation.
Thermo Fisher Scientific
Thermo Fisher Scientific supplies innovative solutions for the world’s pharmaceutical and biopharmaceutical industries. With applications that span the drug development process – from drug discovery through large-scale commercial production – we provide a broad range of products and services including single-use technologies, high-quality media and sera, freezing and storage equipment, innovative consumables and reagents, purification, and analytics.
Syngene International Ltd.
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated contract research, development and manufacturing organization providing scientific services -- from early discovery to commercial supply. Our innovative capabilities for novel molecular entities (NMEs) cater to pharma, biotech, nutrition, animal health, consumer goods and speciality chemical companies.
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally.